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Mast cells are a component of cancer microenvironment the role of which is com-
plex and poorly understood. Mast cells promote cancer growth by stimulation of neoan-
giogenesis, tissue remodeling and by modulation of the host immune response. The
mediators of cancer promotion include protease-activated receptors, mitogen acti-
vated protein kinases, prostaglandins and histamine. Histamine may induce tumor
proliferation and immunosuppression through H1 and H2 receptors, respectively.
The mast cell-derived modulators of immune response include also interleukin 10
(IL-10), tumor necrosis factor α (TNF-α) and CD30L. Possibly stimulation of an-
giogenesis is the most important. Mast cells release potent proangiogenic factors such
as vascular endothelial growth factor (VEGF), basic fibroblast growth factor
(bFGF), transforming growth factor β (TGF-β), TNF-α and IL-8, and mast cells’ en-
zymes, like metaloproteinases (MMPs), tryptase and chymase participate in ves-
sels’ formation. The anti-cancer actions of mast cells include direct growth inhibi-
tion, immunologic stimulation, inhibition of apoptosis and decreased cell mobility;
the mediators of these processes include chymase, tryptase, TNF-α, IL-1 and IL-6.
The very same mediators may exert both pro- or anti-cancer effects depending on
concentration, presence of cofactors or location of secreting cells. In fact, peri- and
intra-tumoral mast cells may have dissimilar effects. Understanding of the role of
mast cells in cancer could lead to improved prognostication and development of ther-
apeutic methods targeting the mast cells.
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Introduction
Virchow already suspected that inflammation and
cancer are intimately connected; at that time there were
no tools for confirming this view, as well as that of Paget
who coined the “seed and soil” theory. Until recently,
the cancer study has thus concentrated on analyzing
the cancer cells themselves. The bulk of information
available is huge and our understanding of the phe-
nomena behind neoplastic transformation is expand-
ing. Only in the 1980s the concept of microenviron-
ment was introduced. Since when, we have become
increasingly aware of interactions between the cancer
and its environment. The cancer microenvironment in-
cludes fibroblasts and myofibroblasts, extracellular ma-
trix, preexistent and newly forming vessels, as well as
inflammatory cells. The function of the inflammation
may be extremely complex: beside the very obvious im-
munologic reaction against the cancer cells, the par-
ticipants of an inflammatory and reparative process are
truly necessary for cancer progression. In fact, cancer
was regarded as a “non healing wound” [1-3]. While
we are able to produce a sketchy picture of the func-
tion of lymphoid cells or macrophages, understanding
of other participants is scarce or lacking. One of such
forgotten cells of cancer-stromal interaction is the mast
cell (MC) (Fig. 1).
The MCs may be responsible themselves for this rel-
ative negligence. The MCs are usually a minor com-
ponent of the tissue, and quite difficult to detect. A char-
acteristic feature used for MC detection is the expression
of proteinases, such as tryptase and chymase. The ex-
pression of chymase gives a further insight as some MCs
are more equal than others, in fact some express tryptase
only, while others both tryptase and chymase; this may
influence their function [3-5].
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Fig. 1. Mast cells are quite frequently seen as a component of uterine smooth muscle tumors. These cells may interfere
with the mitotic count essential for the assessment of the tumor biology. A) HE, magnification 200×, 
B) immunohistochemistry for tryptase, magnification 200×
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The MC is a ubiquitous bone-marrow derived cell,
a silent inhabitant of most tissues and organs. Its role
becomes important in the very first phases of inflam-
mation and becomes extraordinary in the allergic
process. The relationship between inflammation, mast
cells and cancer might be quite complicated, featur-
ing both promotion and inhibition of the tumor
growth (Fig. 2). 
Mast cells as cancer promoters
The cancer stimulating mechanisms operated by MCs
include participation in immunosuppression, the release
of proangiogenic and mitogenic factors and involvement
in the degradation of the extracellular matrix [6].
The MCs may also directly influence growth of the
cancer cells [7-11]. Yoshii et al. showed that tryptase
may be responsible for stimulation of cancer growth,
specifically through the protease activated receptor
(PAR-2), MAP kinase activation and prostaglandin E2
release. 
The best known mast cell product is histamine and
it can play a role in tumor progression. Bowrey et al.
showed that tumor histamine content correlates pos-
itively with the mast cell count in breast carcinomas
[12]; this suggests that mast cells are indeed the prin-
cipal source of the tumor histamine. Histamine can in-
duce tumor proliferation through H1 receptors and 
suppress the immune system through H2 receptors.
Both may be involved in human carcinogenesis [13].
The presence of H3 and H4 histamine receptors in hu-
man breast carcinoma cells were also described [14].
Activation of H2 receptor by histamine increases cell
proliferation in NMU-induced mammary tumor [15].
What is more, Medina et al. [14] showed a direct cor-
relation of endogenous histamine levels with malignant
behavior of mammary cells. Histamine modulated the
proliferation in MDA-MB-231 breast cancer cells in
a dose-dependent manner. Histamine also plays a role
in the growth-inducing activity of mast cell culture me-
dia on thyroid carcinoma cells [16]. Stabilization of mast
cells could decrease neurofibroma growth [17]. Mast
cells were shown to be required for generation of neu-
rofibromas in neurofibromatosis type 1, both in humans
and in animal models [18]. Yoshida et al. [19] stud-
ied histamine-positive cells and plasma histamine
levels in NF1 patients with different types of neurofi-
bromas. In cutaneous neurofibromas and diffuse 
plexiform neurofibromas there were many histamine-
positive cells, though, in nodular plexiform neurofi-
3bromas there were only a few. It was suggested that
the number of histamine-positive cells depends on the
size of the tumor and in smaller tumors located 
superficially, the histamine-positive cell counts might
be higher. 
Mast cells may also contribute to cancer growth by
modulation of the immune response. Secretion of his-
tamine, interleukin 10 (IL-10) and tumor necrosis fac-
tor α (TNF-α) leads to suppression of the cellular im-
munity. Mast cell interaction with regulatory T-cell
(Treg) modulates the function of both cell types. Treg
inhibits mast cell progenitors and suppresses degran-
ulation of mature mast cells. Mast cells in turn inhib-
it expression of IL-10 by Treg and promote differenti-
ation of pro-inflammatory ΔTreg [20]. In hepatocellular
carcinoma, mast cell count in combination with Treg
number could predict the outcome more effectively than
the mast cell count alone [21]. In colorectal carcino-
ma, mast cells may play a critical role to reverse the
anti-inflammatory function of the regulatory T-cells
[22]. Mast cells also induce CD8+ T cells activation
and proliferation; in endometrial carcinoma, tryptase-
positive mast cell counts correlate to CD8+ count and
these parameters increase with cancer progression [23].
Hart et al. [24] suggest that mast cells contribute to
the development of basal cell carcinoma by initiating
immunosuppression. They claim that a higher num-
ber of mast cells in non-sun-exposed skin leads to basal
cell carcinoma development. Histamine might also pro-
tect against ionizing radiation, with obvious therapeutic
implications [25]; on the other hand, MDA-MB-231
breast cancer cells were sensitized to radiation by his-
tamine [14]. There are reports that Hodgkin’s lym-
phoma patients with many mast cells in their tumor
tissue have a worse prognosis. Mast cells produce func-
tionally active CD30 ligand (CD30L) and the poorer
prognosis has been proposed to be caused by stimulation
of Reed-Sternberg cells by CD30L [26]. In a pancre-
atic β-cell tumor model, activation of Myc in vivo trig-
gered rapid recruitment of mast cells to the tumor site.
Such a recruitment was necessary for macroscopic tu-
mor expansion [27].
Possibly the most important factor by which mast
cells may influence cancer growth is stimulation of an-
giogenesis. Mast cells seem to stimulate angiogenesis
mainly in the early phase of tumor development, while
at later stages tumor cells become self-sufficient with
regard to production of proangiogenic factors [28]. Se-
creting mast cells can induce and enhance angiogen-
esis via multiple interacting pathways. They release 
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Fig. 2. Tryptase positive cells in the stroma of: malignant melanoma (A); renal urothelial carcinoma (B), 
breast carcinoma (C), and colorectal adenocarcinoma (D)
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4potent proangiogenic factors such as vascular en-
dothelial growth factor (VEGF), basic fibroblast
growth factor (bFGF), transforming growth factor β
(TGF-β), TNF-α and IL-8 [29-31]. Tryptase also has
proangiogenic action with its ability to degrade con-
nective tissue matrix and ability to activate PAR-2 re-
ceptors expressed on endothelial cells [7, 32]. Chymase
was also shown to be pro-angiogenic [33]. Mast cells
secrete also professional extracellular matrix digesters,
such as MMP-2, and they convert pro-MMP-9 (inac-
tive form) into MMP-9 (active form) [28, 34]. Pro-
teinases and heparin released by mast cells stimulate
heparin-binding pro-angiogenic factors located on cell
surfaces and in the extracellular matrix. Histamine,
VEGF, and lipid-derived mediators induce microvas-
cular hyperpermeability. Mast cells recruit macrophages
and lymphocytes, activate platelets and other non-mast
cells which secrete pro-angiogenic factors. ECM re-
modeling and changes in microenvironment may in turn
change the number, function and phenotype of mast
cell population [30]. All of the above-mentioned
functions of mast cells may influence cancer progres-
sion and metastatic spread. 
Mast cells as cancer fighters
The anti-neoplastic actions might include direct in-
hibition of cell growth, increased inflammatory anti-
tumor reaction, induction of apoptosis and decreased
cell mobility. The opposite effects of the same mast cell
might depend on its ability to degranulate or secrete
specific mediators in response to a variance of stimuli.
Tryptase causes tumor cells disruption and chondroitin
sulphate may inhibit tumor cells dissemination and
metastasis formation [21]. Mast cells might also be able
to recruit both M1 and M2 macrophages, which are
well known to have opposite effects on tumor growth.
Another important factor is the heterogeneity of
mast cells, especially the presence of both chymase pos-
itive and chymase negative cells; these may differ in their
products and also in response to stimuli [35].
Some mediators released by mast cells show an in-
hibitory effect on tumor growth and angiogenesis,
specifically TNF-α, IL-1 and IL-6 have been report-
ed to suppress melanoma growth. Additionally, phe-
notype and secretory patterns of mast cells can be al-
tered by microenvironmental factors which result in the
release of specific mediators. For example, low pH pro-
motes IL-4 and IL-6 production without concomitant
histamine release. Some mediators that have well-es-
tablished proangiogenic functions may paradoxically
inhibit progression of the tumor. It is postulated that
histamine can increase prostacyclin synthesis by en-
dothelial cells, and prostacyclin is a potent an-
timetastatic factor [6]. Some studies have shown the
direct tumor cytotoxicity of mast cells. Activation of
TLR2 on mast cells and subsequent release of IL-6 re-
sults in the inhibition of tumor growth both in vitro and
in vivo. Recruitment of NK cells and CD3+ T cells by
mast cells has also been observed [36]. In a mouse
melanoma model, recruitment of eosinophils by
tryptase and promotion of their survival by mast cell
derived IL-5 leads to tumor regression [37].
Clinical impact
The clinical significance of tumor-related mast
cells remains only partially understood. Among many
functions of mast cells promoting tumor growth, their
contribution to neoangiogenesis seems to be most im-
portant. The participation of mast cells in the pro-
gression of cancer and in neoangiogenesis has been
shown in several cancer types; specifically pulmonary
carcinoma [38], colorectal carcinoma [11, 32], neu-
rofibromas [39], prostatic carcinoma [40-42] and var-
ious skin tumors including basal cell carcinoma and
melanomas [6, 8, 43]. Ribatti et al. measured angio-
genesis and microvessel counts in human endometri-
al carcinoma [44]. The number of microvessels was
highly correlated with MC tryptase-positive cell
counts, moreover these parameters raised with tumor
progression. A similar outcome in the uterine cervix car-
cinoma [45] and in pulmonary adenocarcinoma [46]
was observed.
Carlini et al. showed that patients with the non small
cell pulmonary carcinoma and a high chymase positive
mast cell count inside the tumors had higher vascular
density. It has also been shown that the patients with
higher peritumoral mast cell count had a higher
chance of survival [38]. Mauro et al. performed a sim-
ilar analysis of colorectal carcinoma. They reported a cor-
relation between mast cell counts and vascular densi-
ty, and a higher survival rate for patients with lower
mast cell counts at the tumoral/stromal interface [11].
Ribatti et al. [47] found the density of mast cells to par-
allel microvessel density in progression of gastric car-
cinoma. This relationship was seen for both chymase
and tryptase.
Location (perhaps) matters! 
The issue of MCs’ clinical impact is further com-
plicated by the existence of both intratumoral and per-
itumoral mast cells (Fig. 3) with a possibly divergent
significance. Most studies suggest that peritumoral mast
cells are more numerous than intratumoral; it was also
observed that intratumoral mastocytes contain less gran-
ules; this might indicate a more extensive secretion [11,
32, 38].
A high intratumoral mast cell count was identified
as a good prognostic factor in prostatic cancer by Fleis-
chmann et al. [40] and Nonomura et al. [42]. It was
an independent factor only in the latter study, though.
Johansson et al. [41] confirmed these results. The same
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5study showed that a patient with a high peritumoral
mast cells count fare significantly worse. The two pop-
ulations of mast cells would thus have opposite effects
on survival. 
It was postulated that mast cells accumulate around
melanomas and promote their growth, specifically by
the release of proangiogenic factors. In fact, peritumoral
mast cell counts correlate strongly with microvessel den-
sity, presence of the metastases and prognosis [9, 31,
48, 49]. Melanoma cells may attract mast cells by pro-
ducing mast cell chemotactic/mitogenic factors such
as IL-3 or FGF-2. The recruitment of mast cells, and
subsequent release of heparin, bFGF, histamine, or
TNF-α favors tumor progression, featuring a self-per-
petuating regulatory loop [48, 50].
In addition to the clinical significance of mast cells,
their participation in the process of carcinogenesis is of
particular interest; however this topic is not well ex-
plored.
Mast cells may promote the growth of cancer cells
directly (vide supra). Mast cells have also been shown
to regulate proliferation of blood vessels, and to par-
ticipate in induction of angiogenic switch, necessary for
a fully malignant phenotype. Wilk et al. [51] have seen
a stepwise increase of tryptase-positive and chymase-
positive mast cells from normal mucosa, to cervical in-
traepithelial neoplasia, and ultimately to invasive cer-
vical carcinoma. A similar progression of mast cell num-
bers was described for oral dysplasia and cancer [52].
In addition, mast cells were also shown to participate
in the progression of cutaneous tumors. Our group has
suggested a possible role of MCs in progression from
melanocytic nevus to melanoma [53].
Possible therapeutic impact
As any important factor in cancer pathogenesis, tu-
mor-associated mast cells may represent a target for
treatment. Bowrey et al. [12] used cimetidine in breast
cancer patients. This compound blocks histamine re-
ceptors, but is also known to inhibit activation of mast
cells. The study showed only a minimal and non sig-
nificant effect on tumor growth. As tryptase and chy-
mase are important for cancer progression, inhibition
of these proteinases might be promising. Compounds
targeting tryptase are underdeveloped, and although
designed as anti-allergic, might have an antitumor ef-
fect as well [54, 55].
Some of the currently known “targeted” therapeu-
tic methods may target mast cells as well. This may
be voluntary or an unexpected effect. The c-kit tyro-
sine kinase is targeted by imatinib and other com-
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Fig. 3. Tryptase-positive cells in the stroma of colorectal adenocarcinoma (A), and an even higher number of tryptase-
positive cells at the tumor interface (B). Immunohistochemistry, magnification 200×
A B
6pounds. SCF/c-Kit signaling is crucial for mast cells [56].
The former is selectively inhibiting the receptor altered
in gastrointestinal stromal tumors, but not the wild form
present on mast cells. Other formulations, as antian-
giogenic sunitimib, sorafenib or nilotinib may have
a broader spectrum of action. What is more, the non-
neoplastic cancer-accompanying cells might be less
prone to develop mutation-driven resistance. Such an-
titumor effect mediated by mast cell inhibition was
shown in neurofibromas [18], both in the experimen-
tal model of neurofibromatosis and in single human sub-
jects. 
The net effect on cancer development may be dif-
ficult to assess, with unexpected results due to the com-
plexity of regulatory networks.
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